Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | FPR1 | P21462 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525273 | 1.00 | FPR2 (0.47) | FPR2TP53LMNASMN1; SMN2FPR1 | |
| SCHEMBL4525604 | 0.80 | TSHR (0.39) | FPR2TP53LMNASMN1; SMN2POLB | |
| SCHEMBL19098411 | 0.80 | ALDH1A1 (0.57) | TP53LMNASMN1; SMN2POLBTSHR | |
| SCHEMBL30301910 | 0.80 | ALDH1A1 (0.57) | TP53LMNASMN1; SMN2POLBTSHR | |
| SCHEMBL1983987 | 0.78 | NPC1 (0.60) | SMN1; SMN2GAALIPGALDH1A1 | |
| SCHEMBL12502368 | 0.77 | NOTUM (0.43) | LMNALIPGALDH1A1 | |
| SCHEMBL4525414 | 0.75 | NOTUM (0.56) | TP53SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16289034 | 0.75 | FPR2 (0.49) | FPR2LIPGALDH1A1 | |
| SCHEMBL16289033 | 0.75 | FPR2 (0.49) | FPR2LIPGALDH1A1 | |
| SCHEMBL870385 | 0.75 | RIPK1 (0.48) | TP53LMNASMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | FPR2 3158/4885TP53 1574/4885LMNA 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.